These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 4115837)

  • 1. Response to levodopa therapy in striatonigral degeneration.
    Izumi K
    Lancet; 1972 Sep; 2(7779):707. PubMed ID: 4115837
    [No Abstract]   [Full Text] [Related]  

  • 2. Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation.
    Sharpe JA; Rewcastle NB; Lloyd KG; Hornykiewicz O; Hill M; Tasker RR
    J Neurol Sci; 1973 Jul; 19(3):275-86. PubMed ID: 4716845
    [No Abstract]   [Full Text] [Related]  

  • 3. Striatonigral degeneration response to levodopa therapy.
    Rajput AH; Kazi KH; Rozdilsky B
    J Neurol Sci; 1972 Jul; 16(3):331-41. PubMed ID: 5038888
    [No Abstract]   [Full Text] [Related]  

  • 4. Levodopa therapy in striatonigral degeneration.
    Weinmann RL
    Lancet; 1972 Oct; 2(7781):828. PubMed ID: 4116273
    [No Abstract]   [Full Text] [Related]  

  • 5. Levodopa therapy in striatonigral degeneration.
    Andrews JM
    Lancet; 1972 Jul; 2(7767):88. PubMed ID: 4113323
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).
    Hornykiewicz O
    Br Med Bull; 1973 May; 29(2):172-8. PubMed ID: 4356552
    [No Abstract]   [Full Text] [Related]  

  • 7. Failed levodopa therapy in striato-nigral degeneration.
    Izumi K; Inoue N; Shirabe T; Miyazaki T; Kuroiwa Y
    Lancet; 1971 Jun; 1(7713):1355. PubMed ID: 4103418
    [No Abstract]   [Full Text] [Related]  

  • 8. Physiologic, biochemical, and pathological backgrounds of levodopa and possibilites for the future.
    Hornykiewicz OD
    Neurology; 1970 Dec; 20(12):Suppl:1-5. PubMed ID: 5529913
    [No Abstract]   [Full Text] [Related]  

  • 9. L-dopa in Parkinsonism. A possible mechanism of action.
    Ng LK; Chase TN; Colburn RW; Kopin IJ
    Neurology; 1972 Jul; 22(7):688-96. PubMed ID: 4673250
    [No Abstract]   [Full Text] [Related]  

  • 10. A clinical study of methysergide in Parkinsonism: evidence against a serotonergic mechanism.
    Klawans HL; Ringel SP
    J Neurol Sci; 1973 Aug; 19(4):399-405. PubMed ID: 4724817
    [No Abstract]   [Full Text] [Related]  

  • 11. A familial neurological disease with symptomatic response to levodopa.
    Ziegler DK; Schimke RN; Kepes J; Rose D; Klinkerfuss G
    Trans Am Neurol Assoc; 1971; 96():330-2. PubMed ID: 5159126
    [No Abstract]   [Full Text] [Related]  

  • 12. Subregional loss of putaminal efferents to the basal ganglia output nuclei may cause parkinsonism in striatonigral degeneration.
    Goto S; Matsumoto S; Ushio Y; Hirano A
    Neurology; 1996 Oct; 47(4):1032-6. PubMed ID: 8857740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of response to levodopa in Parkinson's disease.
    Mones RJ
    JAMA; 1971 Aug; 217(9):1245. PubMed ID: 5109470
    [No Abstract]   [Full Text] [Related]  

  • 14. Sporadic and familial parkinsonism and motor neuron disease.
    Brait K; Fahn S; Schwarz GA
    Neurology; 1973 Sep; 23(9):990-1002. PubMed ID: 4737691
    [No Abstract]   [Full Text] [Related]  

  • 15. Levadopa and anticholinergic drugs in Parkinsonism.
    Sourkes T
    Br Med J; 1971 Sep; 3(5776):703-4. PubMed ID: 5569560
    [No Abstract]   [Full Text] [Related]  

  • 16. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration.
    Goto S; Hirano A; Matsumoto S
    Neurology; 1990 Jul; 40(7):1051-6. PubMed ID: 2192300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dopaminergic conception of Parkinsonism and its treatment with L-DOPA].
    Levin SL
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(9):1418-26. PubMed ID: 4349303
    [No Abstract]   [Full Text] [Related]  

  • 18. DOPA-responsive dystonic parkinsonism--pathophysiologic considerations.
    Segawa M; Nishiyama N; Nomura Y
    Adv Neurol; 1999; 80():389-400. PubMed ID: 10410746
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of Parkinson's disease with L-dopa].
    Guglielmi L; Vecchi L
    Clin Ter; 1970 May; 53(3):259-69. PubMed ID: 4917328
    [No Abstract]   [Full Text] [Related]  

  • 20. Ro 4-4602 and levodopa in the treatment of Parkinsonism.
    Miller EM; Wiener L
    Neurology; 1974 May; 24(5):482-6. PubMed ID: 4857107
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.